What question did this study set out to answer?

To evaluate how the intensification of topical medication regimens influences clinical failure rates and economic costs in patients with open-angle glaucoma or ocular hypertension.

October 29, 2020Journal of Glaucoma

Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis

View Full Paper

Ask AI

Bookmark

Authors

APAnik R. PatelVancouver Coastal Health GSGail F. SchwartzGlaucoma Associates of Texas JCJoanna CampbellAbbVie (United States)

Discussion

Member takes

Implication

Retrospective claims study reveals escalating costs and higher re-intensification rates with additional eye drops in glaucoma, highlighting diminishing clinical returns from topical therapy.

Key Points

To evaluate how the intensification of topical medication regimens influences clinical failure rates and economic costs in patients with open-angle glaucoma or ocular hypertension.
Retrospective analysis of administrative claims data from the IQVIA PharMetrics Plus database (January 2011 to July 2017) examining N=48,402 patients initiating or intensifying treatment with 1 to 4 topical glaucoma drug classes between January 2012 and July 2015.
Patients with prior open-angle glaucoma surgery or equal or greater topical medication classes during the preindex period were excluded, with outcomes tracked over a 24-month postindex follow-up.
Treatment augmentation rates rose with the number of baseline drug classes: subsequent medication addition or laser/surgical procedures occurred in 7.8%, 12.2%, 17.2%, and 22.6% of patients at 12 months, and 12.6%, 18.5%, 25.9%, and 33.7% at 24 months for cohorts on 1, 2, 3, or 4 medication classes, respectively.
Mean (SD) eye-related outpatient costs over 24 months increased progressively with each additional baseline medication class: $1,610 ($3,460) for 1 class, $2,418 ($4,863) for 2 classes, $2,872 ($5,110) for 3 classes, and $3,751 ($6,608) for 4 classes.

Cite This Study

Patel et al. (2020) studied this question.

synapsesocial.com/papers/6a95ca67fbcc90fe2d539488 https://doi.org/10.1097/ijg.0000000000001730

View Full Paper

Ask AI

Bookmark

Implication

Retrospective claims study reveals escalating costs and higher re-intensification rates with additional eye drops in glaucoma, highlighting diminishing clinical returns from topical therapy.

Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider